firstwordpharmaDecember 04, 2018
Tag: Announce , Sinclair Pharma , expansion , Announce
Sinclair Pharma Limited, a global aesthetics company headquartered in London, today announced that, effective at the end of the year, Doug Abel has resigned his position as Head of North America and President of Silhouette Lift, Inc., to lead a new aesthetic venture and has licensed the U.S. sales and marketing rights to the Refine Support System® from Sinclair. The Company also announced the appointment of Amber Edwards to the positions of President, Silhouette Lift, Inc., and Head of North America for Sinclair Pharma.
In her new role, Ms. Edwards will lead commercial operations and oversee the growth and expansion of the U.S. team, including an ongoing expansion of the U.S. field sales team as well as advancement of the existing line of products and pipeline into the United States and Canada. Ms. Edwards' new role will take effect on December 1, 2018.
Ms. Edwards joins Sinclair with more than 20 years of experience in pharmaceuticals and medical devices. She most recently served as Vice President, International Strategic Marketing, at Allergan. In this role, she had strategic responsibility for the medical aesthetics franchise for all markets outside of the U.S., leading critical market launches, innovative medical education initiatives, and spearheading consumer platforms to drive expansion and acceptance of the aesthetics category. Prior to her time abroad with Allergan, Ms. Edwards was head of marketing for Allergan's U.S. dry eye franchise, leading Restasis® and the artificial tears business past the $1 billion blockbuster milestone.
"Amber is a highly accomplished pharma executive with a long history of proven success leading major healthcare brands and franchises in both U.S. and international markets, including product launches and portfolio lifecycle management," said Chris Spooner, Chief Executive Officer of Sinclair. "As President, U.S., she will bring continuity to Sinclair's leadership and will be instrumental in leading our expansion and growth in this critical geographic region."
Mr. Spooner continued, "On behalf of the Sinclair executive team, I'd like to thank Doug for his leadership over the last few years in helping us establish a presence in the United States. His commitment and expertise have been critical in building the foundation of our business and establishing a platform for our future growth. We wish him all the best as he continues onto his next venture."
"In my new role, I'm excited to build on the progress that Sinclair has made in marketing our portfolio of differentiated, complementary aesthetic products, including our flagship product, Silhouette InstaLift®," said Ms. Edwards. "I firmly believe that the aesthetics market has reached a tipping point, with a cultural shift and new generation of consumers making interest in physician-administered treatments more acceptable than ever before. The path forward will be through more natural-looking treatments that restore lost volume and reshape for a youthful profile, and Sinclair is in the perfect position to build out a portfolio of minimally-invasive treatments to meet this aspiration."
Sinclair's commitment to continued U.S. expansion and growth highlights the Company's goal of expanding global operations and becoming one of the leaders in aesthetics. In November 2018, Sinclair was acquired by Huadong Medicine Company Limited (HMC), a major Chinese pharmaceutical company that has established a leading aesthetics business in China, in order to strengthen resources and grow its aesthetic product portfolio.
About Sinclair Pharma
Sinclair Pharma, a subsidiary of Huadong Medicine Company Ltd. (HMC), is an international company operating in the fast growth, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The Group has an established sales and marketing presence in the leading EU markets, Brazil, Mexico and South Korea and the US, and a network of international distributors. For more information, visit www.sinclairpharma.com.
"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward‐looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward‐looking statements due to a variety of factors.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: